Literature DB >> 14675314

Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.

K Ikeda1, K Sakai, R Yamamoto, H Hareyama, N Tsumura, H Watari, M Shimizu, H Minakami, N Sakuragi.   

Abstract

It has been suggested that histologic subtype of ovarian cancer is a factor that determines the chemoresponsiveness of tumor. In this study, we wanted to clarify the prognostic significance of histologic subtype and its correlation to expression of chemoresistance-related proteins (CRPs) in ovarian cancer. A total of 93 stage II-IV ovarian cancers, where the proportion of serous, endometrioid, mucinous, and clear cell subtype was 61.3%, 14.0%, 7.5%, and 17.2%, respectively, were investigated for glutathione S-transferase-pi (GST-pi), MDR (multidrug resistance)-1, and p53 expression using immunohistochemistry. GST-pi expression was detected in 62.4% of the tumors and was not related to histologic subtype of tumor. MDR-1 expression was observed in 12.9% of the tumors tested and was more frequently detected in clear cell adenocarcinomas than other histologic subtypes of tumor (10/ 16 vs. 2 / 77, P < 0.001). P53 expression was found in 49.1% of serous, 53.8% of endometrioid, and 50% of mucinous adenocarcinomas. In contrast, none of 16 clear cell adenocarcinomas showed positive p53 staining. In univariate analysis, no direct correlations were found between CRPs and overall survival. Histology of mucinous/clear cell tumors (P = 0.0063), as well as FIGO stage III/IV (P = 0.0091) and residual tumor >or= 2 cm (P = 0.0045), was found to have independent prognostic value in multivariate analysis. In conclusion, histologic subtype proved to be the significant independent prognostic factor in addition to FIGO stage and residual tumor in stage II-IV ovarian cancer. GST-pi, MDR-1, and p53 expression pattern is closely related to histologic subtype of ovarian cancer, although they are not significant predictors of survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675314     DOI: 10.1111/j.1525-1438.2003.13381.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  15 in total

1.  Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.

Authors:  Koji Matsuo; Michele L Eno; Edward H Ahn; Mian M K Shahzad; Dwight D Im; Neil B Rosenshein; Anil K Sood
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

2.  Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.

Authors:  Paweł Surowiak; Verena Materna; Irina Kaplenko; Marek Spaczyński; Manfred Dietel; Hermann Lage; Maciej Zabel
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

Review 3.  Survivorship as an element of clinical trials in ovarian cancer.

Authors:  Jessica N McAlpine; Lari B Wenzel
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

Review 4.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

5.  Proteomic analysis of glutathione S-transferase isoforms in mouse liver mitochondria.

Authors:  Hai-Dan Sun; Ya-Wei Ru; Dong-Juan Zhang; Song-Yue Yin; Liang Yin; Ying-Ying Xie; You-Fei Guan; Si-Qi Liu
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

Review 6.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

7.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

8.  Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kosuke Miyai; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-10-24       Impact factor: 4.064

9.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

10.  Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US.

Authors:  Maria Theresa M Redaniel; Adriano Laudico; Maria Rica Mirasol-Lumague; Adam Gondos; Gemma Leonora Uy; Jean Ann Toral; Doris Benavides; Hermann Brenner
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.